Gene therapy for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This 96-week study tests OCUL101, a new gene therapy treatment, for wet AMD (a serious eye condition that causes vision loss). The trial will check if OCUL101 works better than or as well as current treatments, and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50–89 years old
- Have wet AMD in at least one eye that has never been treated before
- Vision between 20/40 and 20/320 in the study eye
- Clear enough eye tissue to get good quality imaging of the retina
- Willing to use contraception if of childbearing potential
- No recent eye surgery, cancer, stroke, or major infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
This trial tests a new CRISPR-based gene therapy injected into the eye to treat wet age-related macular degeneration (AMD). It aims to stop the growth of abnormal blood vessels that damage your vision.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
Hear when a new Adults With Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.